Liposome

Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study

Friday, June 11, 2021 - 8:00am

Innocan believes this result to be extremely encouraging, given the 24-hour maximum CBD presence in the bloodstream when administered through traditional channels.

Key Points: 
  • Innocan believes this result to be extremely encouraging, given the 24-hour maximum CBD presence in the bloodstream when administered through traditional channels.
  • This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders.
  • Innocan Pharma is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD.
  • The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study

Friday, May 14, 2021 - 8:28am

This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders.

Key Points: 
  • This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders.
  • Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Coronavirus using CBD.
  • Innocan Israel plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications.
  • The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.\n'

LIPAC Oncology Names Daniel K. Spiegelman as Independent Board Advisor

Thursday, May 13, 2021 - 1:01pm

b'MENLO PARK, Calif., May 13, 2021 /PRNewswire/ --LIPAC Oncology LLC., a pharmaceutical company utilizing its liposome-bound nano-technology platform to provide precision targeted cancer drugs for the treatment of multiple tumor types, today announced the appointment of Daniel K. Spiegelman as an independent board advisor.\n"We are excited to welcome Dan as an advisor," said Will Robberts, President of LIPAC Oncology.

Key Points: 
  • b'MENLO PARK, Calif., May 13, 2021 /PRNewswire/ --LIPAC Oncology LLC., a pharmaceutical company utilizing its liposome-bound nano-technology platform to provide precision targeted cancer drugs for the treatment of multiple tumor types, today announced the appointment of Daniel K. Spiegelman as an independent board advisor.\n"We are excited to welcome Dan as an advisor," said Will Robberts, President of LIPAC Oncology.
  • He has previously served on a number of additional public and private biotechnology company boards.
  • "I look forward to working with the team and providing strategic guidance as they advance this important new technology.
  • LiPax, its lead investigational candidate for the treatment of non-muscle invasive bladder cancer, is in Phase 2b development.

Worldwide Portable Compressor Nebulizer Industry to 2025 - Increasing Demand for Home Healthcare Devices Presents Opportunities

Tuesday, April 20, 2021 - 2:45pm

In Nov 2018, Koninklijke Philips launched InnoSpire Go portable nebulizer in the U.S.

Key Points: 
  • In Nov 2018, Koninklijke Philips launched InnoSpire Go portable nebulizer in the U.S.
  • The product is the smallest and lightest portable handheld nebulizer.\n2.
  • In October 2018, Pari Pharma gets approval for its e-FLOW technology device LAMIRA, which is the only nebulizer system to deliver amikacin liposome inhalation suspension (ARIKAYCE).
  • The projections are calculated using proven research methodologies.\nThe report has been compiled through extensive primary and secondary research.

MixX Lab's Idebenone 1% Antioxidant Tightening Essences Introduces Breakthrough Liposomal Technology

Wednesday, March 31, 2021 - 5:00pm

MixX Laboratory introduces their Idebenone 1% Antioxidant Tightening Essence, which is formulated using Liposomal Technology.

Key Points: 
  • MixX Laboratory introduces their Idebenone 1% Antioxidant Tightening Essence, which is formulated using Liposomal Technology.
  • MixX Laboratory's Idebenone Essence has been bonded with Liposomal Technology.
  • MixX Laboratory uses an exclusive IDB Nano-Liposome encapsulation technology to 'lock the freshness' into the ingredient, thus preserving its potency.
  • Through these findings, MixX Laboratory's Liposomal breakthrough formula has successfully been adopted in Idebenone's 1% Antioxidant Tightening Essence.

Global Liposomal Drug Delivery Devices Market 2020-2030: COVID-19 Impacts, Growth and Changes

Thursday, February 4, 2021 - 8:15pm

Liposomal Drug Delivery Devices Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global liposomal drug delivery devices market.

Key Points: 
  • Liposomal Drug Delivery Devices Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global liposomal drug delivery devices market.
  • The liposomal drug delivery devices market consists of sales of liposomal drug delivery devices and related services by entities (organizations, sole traders, and partnerships) that manufacture liposomal drug delivery devices.
  • The liposomal drug delivery devices market covered in this report is segmented by type into liposomal doxorubicin; liposomal paclitaxel; liposomal amphotericin B; others.
  • Global Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
    4.2.

Oncology Pharma Extends Its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Human Oncology

Wednesday, February 3, 2021 - 1:30pm

SAN FRANCISCO, CA, Feb. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in Human Oncology.

Key Points: 
  • SAN FRANCISCO, CA, Feb. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in Human Oncology.
  • NanoSmart's patented, human-derived, anti-nuclear antibody (ANA) binds to necrotic tissue that is present in and around all solid tumors.
  • Lipid nanoparticles, such as liposomes and nanoemulsions, can be used to encapsulate existing and FDA-approved active pharmaceutical ingredients (APIs).
  • For additional information, please contact the Oncology Pharma at:

Global Liposomal Drug Delivery Devices Market 2020: Major Players are Fudan-Zhangjiang, Pacira, Johnson and Johnson, Gilead Sciences, Novartis, Luye Pharma, CSPC, Ipsen and Teva Pharma - ResearchAndMarkets.com

Wednesday, February 3, 2021 - 11:26am

Liposomal Drug Delivery Devices Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global liposomal drug delivery devices market.

Key Points: 
  • Liposomal Drug Delivery Devices Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global liposomal drug delivery devices market.
  • Major players in the liposomal drug delivery devices market are Fudan-Zhangjiang, Pacira, Johnson and Johnson, Gilead Sciences, Novartis, Luye Pharma, CSPC, Ipsen (Onivyde) and Teva Pharmaceutical.
  • The liposomal drug delivery devices market consists of sales of liposomal drug delivery devices and related services by entities (organizations, sole traders, and partnerships) that manufacture liposomal drug delivery devices.
  • The liposomal drug delivery devices market covered in this report is segmented by type into liposomal doxorubicin; liposomal paclitaxel; liposomal amphotericin B; others.

Innocan Pharma Announces Successful Production of CBD Loaded Liposomes under Aseptic Conditions

Friday, January 22, 2021 - 7:00am

Dr. Ahuva Cern, the project manager in Professor Barenholz's laboratory at the Hebrew University, Jerusalem, stated: "We succeeded in manufacturing CBD-loaded Liposomes under aseptic conditions.

Key Points: 
  • Dr. Ahuva Cern, the project manager in Professor Barenholz's laboratory at the Hebrew University, Jerusalem, stated: "We succeeded in manufacturing CBD-loaded Liposomes under aseptic conditions.
  • Those liposomes loaded with CBD were found to be sterile and conform to the pyrogenicity limits.
  • This achievement is a 'must' step as we are looking forward to large scale production and later commercial size production."
  • The founders and officers of Innocan Israel have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

Cymbiotika Introduces Liposomal Sulforaphane Matrix

Friday, December 18, 2020 - 4:30pm

Cymbiotika , a leading dietary supplement brand known for creating pure, clinically backed supplements, announced today the release of Liposomal Sulforaphane Matrix to support wellness through detoxification and healthy inflammation response.

Key Points: 
  • Cymbiotika , a leading dietary supplement brand known for creating pure, clinically backed supplements, announced today the release of Liposomal Sulforaphane Matrix to support wellness through detoxification and healthy inflammation response.
  • Our Liposomal Sulforaphane Matrix works to activate cellular detoxification by inducing the three primary phases of detoxification.
  • Cymbiotikas Liposomal Sulforaphane Matrix is an easy to use liquid; no capsules, powders or tablets to swallow.
  • Cymbiotikas Liposomal Sulforaphane Matrix is also available in Cymbiotikas Immune Nutrition Bundle (with Elderberry and D3K2) and Cellular Cleanse Bundle (with Regenesis, B12 and Charcoal).